245 related articles for article (PubMed ID: 22283413)
1. Continuous flow synthesis. A pharma perspective.
Malet-Sanz L; Susanne F
J Med Chem; 2012 May; 55(9):4062-98. PubMed ID: 22283413
[No Abstract] [Full Text] [Related]
2. Could pharma open its drug freezers?
Mullard A
Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278
[No Abstract] [Full Text] [Related]
3. Wrong questions, wrong answers? Are we getting the drugs we need?
Lipworth WL; Kerridge IH; Day RO
Clin Pharmacol Ther; 2012 Mar; 91(3):367-9. PubMed ID: 22343808
[No Abstract] [Full Text] [Related]
4. The role of discovery DMPK scientists in industry: where do we go from here?
Moriwaki T
Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
[No Abstract] [Full Text] [Related]
5. Learning lessons from drugs that have recently entered the market.
Teague SJ
Drug Discov Today; 2011 May; 16(9-10):398-411. PubMed ID: 21414418
[TBL] [Abstract][Full Text] [Related]
6. Where do innovative drugs come from?
Higgs G
Drug Discov Today; 2011 Nov; 16(21-22):907-9. PubMed ID: 21889605
[No Abstract] [Full Text] [Related]
7. Can biochemistry drive drug discovery beyond simple potency measurements?
Chène P
Drug Discov Today; 2012 Apr; 17(7-8):388-95. PubMed ID: 22326379
[TBL] [Abstract][Full Text] [Related]
8. Chemistry strategies in early drug discovery: an overview of recent trends.
Colombo M; Peretto I
Drug Discov Today; 2008 Aug; 13(15-16):677-84. PubMed ID: 18675762
[TBL] [Abstract][Full Text] [Related]
9. Outsourcing chemical synthesis in the drug discovery process.
Festel G
Drug Discov Today; 2011 Mar; 16(5-6):237-43. PubMed ID: 21262378
[TBL] [Abstract][Full Text] [Related]
10. Highly engineered biocatalysts for efficient small molecule pharmaceutical synthesis.
Lalonde J
Curr Opin Biotechnol; 2016 Dec; 42():152-158. PubMed ID: 27261887
[TBL] [Abstract][Full Text] [Related]
11. Getting physical to fix pharma.
Connelly PR; Vuong TM; Murcko MA
Nat Chem; 2011 Aug; 3(9):692-5. PubMed ID: 21860457
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
[TBL] [Abstract][Full Text] [Related]
13. Large-scale oxidations in the pharmaceutical industry.
Caron S; Dugger RW; Ruggeri SG; Ragan JA; Ripin DH
Chem Rev; 2006 Jul; 106(7):2943-89. PubMed ID: 16836305
[No Abstract] [Full Text] [Related]
14. Continuous flow microreactors for drug discovery.
Watts P
Curr Opin Drug Discov Devel; 2004 Nov; 7(6):807-12. PubMed ID: 15595441
[TBL] [Abstract][Full Text] [Related]
15. Medicinal chemistry in drug discovery in big pharma: past, present and future.
Campbell IB; Macdonald SJF; Procopiou PA
Drug Discov Today; 2018 Feb; 23(2):219-234. PubMed ID: 29031621
[TBL] [Abstract][Full Text] [Related]
16. Macro trends in pharmaceutical innovation.
Cohen FJ
Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
[TBL] [Abstract][Full Text] [Related]
17. The right medicines--just not enough of them.
Honig PK
Clin Pharmacol Ther; 2012 Mar; 91(3):369-72. PubMed ID: 22343809
[No Abstract] [Full Text] [Related]
18. An open source pharma roadmap.
Balasegaram M; Kolb P; McKew J; Menon J; Olliaro P; Sablinski T; Thomas Z; Todd MH; Torreele E; Wilbanks J
PLoS Med; 2017 Apr; 14(4):e1002276. PubMed ID: 28419094
[TBL] [Abstract][Full Text] [Related]
19. An industry perspective on tiered approach to the investigation of metabolites in drug development.
Huskey SE; Li W; Mangold JB; Flarakos J
Bioanalysis; 2014 Mar; 6(5):617-28. PubMed ID: 24620804
[TBL] [Abstract][Full Text] [Related]
20. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
Lee JA; Uhlik MT; Moxham CM; Tomandl D; Sall DJ
J Med Chem; 2012 May; 55(10):4527-38. PubMed ID: 22409666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
